BR112013014586A2 - agente e método de formação de imagem - Google Patents

agente e método de formação de imagem

Info

Publication number
BR112013014586A2
BR112013014586A2 BR112013014586A BR112013014586A BR112013014586A2 BR 112013014586 A2 BR112013014586 A2 BR 112013014586A2 BR 112013014586 A BR112013014586 A BR 112013014586A BR 112013014586 A BR112013014586 A BR 112013014586A BR 112013014586 A2 BR112013014586 A2 BR 112013014586A2
Authority
BR
Brazil
Prior art keywords
hce
imaging agent
intracellular
cells
mono
Prior art date
Application number
BR112013014586A
Other languages
English (en)
Inventor
Hastings Drummond Alan
Festus Charles Moffat David
Hugh Charlton Michael
John Davies Steven
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of BR112013014586A2 publication Critical patent/BR112013014586A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"agente e método de formação de imagem" um agente de formação de imagem para células que produzem um sinal de formação de imagem intracelular proporcional à quantidade de hce- 1 nas células de maneira independente da quantidade de hce-2 e/ou hce-3 nas células, o dito agente de formação de imagem sendo um conjugado covalente de (a) um agente de formação de imagem e (b) um éster de aminoácido alfa mono ou di-substituído, em que (a) é diretamente ligado a (b) ou (a) é indiretamente ligado a (b) por um radical ligante e em que a dita ligação direta ou indireta ocorre por intermédio do grupo amino de (b) e em que o grupo amino não é diretamente ligado a um grupo carbonila e em que a dita parte do éster de aminoácido alfa mono ou di-substituído é seletivamente hidrolisável à parte de ácido carboxílico correspondente pela enzima carboxilesterase intracelular hce-1 com relação às enzimas intracelulares hce-2 ou hce-3.
BR112013014586A 2010-12-17 2011-12-16 agente e método de formação de imagem BR112013014586A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021467.4A GB201021467D0 (en) 2010-12-17 2010-12-17 Imaging agents
PCT/GB2011/001729 WO2012080705A1 (en) 2010-12-17 2011-12-16 Imaging agents

Publications (1)

Publication Number Publication Date
BR112013014586A2 true BR112013014586A2 (pt) 2019-02-19

Family

ID=43598579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014586A BR112013014586A2 (pt) 2010-12-17 2011-12-16 agente e método de formação de imagem

Country Status (14)

Country Link
US (1) US20140010762A1 (pt)
EP (1) EP2651454A1 (pt)
JP (1) JP2013545795A (pt)
KR (1) KR20140004676A (pt)
CN (1) CN103391789A (pt)
AU (1) AU2011343017A1 (pt)
BR (1) BR112013014586A2 (pt)
CA (1) CA2821856A1 (pt)
EA (1) EA201370121A1 (pt)
GB (1) GB201021467D0 (pt)
MX (1) MX2013006393A (pt)
SG (1) SG191121A1 (pt)
WO (1) WO2012080705A1 (pt)
ZA (1) ZA201304156B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI3222616T1 (sl) 2012-10-17 2019-10-30 Macrophage Pharma Ltd N-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2H)-IL)-3,5- difluorofenil)etil)-L-alanin in njegov terbutil ester
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69501981T2 (de) * 1994-01-12 1998-12-10 Bracco Int Bv Liganden und deren metallkomplexe
US20030082106A1 (en) * 2000-01-22 2003-05-01 Aleksandr Nivorozhkin Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
AU2002244568A1 (en) * 2001-03-14 2002-09-24 Mcgill University Individualization of therapy with antipsychotics
EP1660519B1 (en) * 2003-07-29 2014-05-14 Immunomedics, Inc. Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule
US7091211B2 (en) * 2003-07-31 2006-08-15 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity

Also Published As

Publication number Publication date
GB201021467D0 (en) 2011-02-02
SG191121A1 (en) 2013-07-31
EP2651454A1 (en) 2013-10-23
ZA201304156B (en) 2014-02-26
US20140010762A1 (en) 2014-01-09
MX2013006393A (es) 2013-09-13
WO2012080705A1 (en) 2012-06-21
KR20140004676A (ko) 2014-01-13
EA201370121A1 (ru) 2013-08-30
CN103391789A (zh) 2013-11-13
CA2821856A1 (en) 2012-06-21
JP2013545795A (ja) 2013-12-26
AU2011343017A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
BR112012011427A2 (pt) moduladores seletivos de receptor de esfingosina 1 fosfato e métodos de ´sintese quiral
NZ612320A (en) Materials and methods for conjugating a water soluble fatty acid derivative to a protein
WO2011028698A3 (en) Mri and optical assays for proteases
BR112012011430A2 (pt) moduladores de receptor de esfingosina 1 fosfato e métodos de síntese quiral
HRP20130618T1 (en) Methods of using mirna for detection of in vivo cell death
WO2009048072A1 (ja) 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体
BR112013005818A8 (pt) sistema aglutinante agrícola incluíndo açúcar de carboidrato e água, mistura agrícola compreendendo o dito aglutinante e processo de formação do mesmo
WO2009102446A3 (en) Fish assay for eml4 and alk fusion in lung cancer
EP3206034A3 (en) Use of fatty acids in methods for detecting cancer
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
AU2012356133A8 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
BR112014032623A2 (pt) sistema de interface de paciente; e método de prevenção de formação de marcas vermelhas por uma interface de paciente sobre a pele de um paciente
WO2012008860A3 (en) Bacterial nitroreductase enzymes and methods relating thereto
BR112012030561A2 (pt) sistema dealívio de tensão de implante de glossoplastia, método para indicar uma quanidade de força aplicada pela língua de um indivíduo a um sistema implantável e sistema implantável configurado para indicar uma quantidade de força aplicada pela língua de um indivíduo ao sistema implantável
BR112012016463A2 (pt) método e aparelho para medir a eficácia de extermínio de um desinfetante.
BR112013014586A2 (pt) agente e método de formação de imagem
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
BR112012011431A2 (pt) moduladores heterocíclicos seletivos de receptor de esfingosina 1 fosfato
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
Shioji et al. Synthesis and properties of fluorescence probe for detection of peroxides in mitochondria
CA2874960C (en) Euglobulin-based method for determining the biological activity of defibrotide
BRPI0910403A8 (pt) Uso de um agente traçador de mpi, e, método para o monitoramento visual de um produto biocompatível.
MX2013006361A (es) Agtr1 como marcador para terapias combinadas de bevacizumab.
BR0316782A (pt) Produto de leite fermentado, processo para preparação de um produto de leite fermentado e uso da linhagem cnrz 244 de lactobacillus helveticus
FR2933696B1 (fr) Procede de synthese d'acides omega-amino-alcanoiques ou de leurs esters a partir d'acides gras naturels.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]